Skip to content
Home
About Us
Our Science
Pegtarazimod
HIE
News
Home
About Us
Our Science
Pegtarazimod
HIE
News
Contact
Home
About Us
Our Science
Pegtarazimod
HIE
News
Home
About Us
Our Science
Pegtarazimod
HIE
News
Contact
Press Releases
Stay up to date on ReAlta’s news, scientific progress, clinical milestones, and mission to address severe inflammatory disease.
Press Release
Apr 08, 2026
ReAlta Life Sciences Closes Oversubscribed $40 Million Financing Round to Advance Pegtarazimod Phase 2 Program in Hypoxic Ischemic Encephalopathy (HIE)
Years
Years
2020
2021
2022
2023
2024
2025
2026
Press Releases
Press Releases
Press Release
Nov 25, 2025
ReAlta Life Sciences Appoints Dr. Howard Berman as Executive Chairman
Press Release
Jul 22, 2025
ReAlta Life Sciences Publishes Data Demonstrating RLS-0071 (pegtarazimod) Reduces Brain Inflammation in Preclinical Hypoxic Ischemic Encephalopathy Model
Press Release
Apr 25, 2025
ReAlta Life Sciences Announces New Clinical Data for RLS-0071 (pegtarazimod) from Hypoxic Ischemic Encephalopathy Program at Pediatric Academic Societies 2025 Meeting
No posts found